SCHEMBL167346

SCHEMBL167346

[2H]C([2H])(c1ccnc(N)c1)n1ccc2c(NC(=O)Nc3ccc(F)cc3)cccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BUB1 O43683 1/20 0.43
RAB9A P51151 4/20 0.42
MAPT P10636 2/20 0.42
EPHB4 P54760 1/20 0.39
CDK8 P49336 1/20 0.39
KCNH3 Q9ULD8 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
RET P07949 1/20 0.37
KDR P35968 1/20 0.37
P2RY1 P47900 1/20 0.37
PTGER3 P43115 1/20 0.37
MET P08581 2/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL166850 0.92 KMT2A (0.42) RAB9AMAPTCDK8MEN1KMT2A
SCHEMBL168670 0.92 MAPT (0.40) BUB1MAPTKDM4EMEN1KMT2A
SCHEMBL168209 0.91 KDR (0.37) RAB9AMAPTCDK8MEN1KMT2A
SCHEMBL168025 0.91 NPC1 (0.43) RAB9AMAPTEPHB4KDM4EMEN1
SCHEMBL165124 0.91 RAB9A (0.43) RAB9AMAPTEPHB4CDK8KDM4E
SCHEMBL165165 0.90 TRPV1 (0.46) RAB9AMAPTEPHB4MEN1KMT2A
SCHEMBL164013 0.89 RAB9A (0.40) RAB9AMAPTCDK8KDM4EMEN1
SCHEMBL168978 0.89 ROCK2 (0.47) RAB9AMAPTCDK8KDM4EMEN1
SCHEMBL165126 0.89 SMN1; SMN2 (0.42) MAPTEPHB4KDM4EMEN1ALDH1A1
SCHEMBL168099 0.88 P2RY1 (0.44) RAB9ANPC1P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US claimed
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 EP disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 BUB1 153/4885RAB9A 2322/4885MAPT 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.